Acumen Pharmaceuticals, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Acumen Pharmaceuticals, Inc. (ABOS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $5.38 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-27.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2023-03-27
- Acumen Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2021-12-31 was $10.76M.
- Acumen Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2021-09-30 was $0.00.
- Acumen Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2021 was $5.38M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | $10.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $10.76M derived: sum of 2 quarters · filed 2023-03-27 | $5.38M 10-K · filed 2023-03-27 | -$5.38M 10-K · filed 2022-03-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$5.38M 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | -$5.38M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |